Blackrock Health Sciences Trust

Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.

The Eaton Vance Tax-Managed Buy-Write Opportunities Fund, a closed-end equity mutual fund, is operated by Eaton Vance Management and co-managed by Parametric Portfolio Associates LLC. Its investment strategy focuses on publicly traded U.S. equities, specifically targeting companies across a diverse range of sectors. A key part of its methodology involves writing (selling) call options on one or more major U.S. indices, covering a substantial portion of its common stock portfolio's value. The fund measures its performance against a suite of benchmarks: the S&P 500 Index, the CBOE S&P 500 BuyWrite Index, the NASDAQ-100 Index, and the CBOE NASDAQ-100 BuyWrite Index. This U.S.-domiciled fund was established on June 30, 2005.

BlackRock Greater Europe Investment Trust plc functions as a closed-ended equity investment vehicle, officially constituted on September 20, 2004, and legally registered in the United Kingdom. While originally formed by BlackRock Fund Managers Limited, its operations are currently overseen by BlackRock Investment Management (UK) Limited. The fund's objective is to deploy capital into public equities throughout Europe, specifically omitting the United Kingdom. Its investment approach concentrates on acquiring value stocks from large-capitalization companies, typically those boasting a market value in excess of €5 billion, across diverse industry segments. The performance of its portfolio is measured against the FTSE World Europe ex UK Index.

Worldwide Healthcare Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. The fund is managed by OrbiMed Capital LLC. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating in the healthcare sector, with an emphasis on pharmaceutical and biotechnology companies. It primarily invests in growth stocks of large-cap companies with a market capitalization of at least $5 billion. The fund employs fundamental analysis with a bottom-up stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the MSCI World Healthcare Index. The fund employs internal research to make its investments. It was formerly known as Finsbury Worldwide Pharmaceutical Trust plc. Worldwide Healthcare Trust PLC was formed in April 1995 and is domiciled in the United Kingdom.

BIOTECH GROWTH TRUST (THE) PLCBIOG · Asset ManagementLondon, United Kingdom

65% matchPublic

The Biotech Growth Trust PLC, a closed-ended equity investment vehicle, was originally established by Frostrow Capital LLP and is jointly managed by OrbiMed Capital LLC. Formed on May 20, 1997, and legally based in the United Kingdom, this trust allocates its capital to global public equity markets. Its primary objective is to invest in shares of companies operating within the biotechnology sector, spanning the full range of market capitalizations. The construction of its investment portfolio relies on rigorous fundamental analysis, and its performance is benchmarked against the NASDAQ Biotechnology Index. It was previously identified as Finsbury Emerging Biotechnology Trust PLC.

The Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund (ETW) is structured as a closed-end equity investment vehicle. Its primary management responsibilities lie with Eaton Vance Management, with supplemental oversight from Parametric Portfolio Associates LLC. This fund allocates capital to publicly traded companies across international stock markets, seeking diversification across numerous industry sectors. A core aspect of its investment approach involves selling call options on various U.S. and foreign indices, covering a significant portion of its common stock assets. Established on September 30, 2005, and domiciled within the United States, the fund assesses its performance against several benchmarks, including the S&P 500 Index, the CBOE S&P 500 BuyWrite Index, the CBOE NASDAQ-100 BuyWrite Index, and the FTSE Eurotop 100 Index.